Skip to main content
Premium Trial:

Request an Annual Quote

Millipore, Caliper, PerkinElmer, Cellexus

Millipore Posts 40-Percent Gain in Q1 Sales, Though Profits Sink 23 Percent
Millipore this week said first-quarter revenues increased 39 percent as R&D spending rose 50 percent and profit slid 23 percent.
Total receipts for the three months ended March 31 increased to $372 million from $268.4 million year over year.
Sales in the company’s Bioprocess segment rose 40 percent to $214.3 million, while Bioscience revenue swelled 51 percent to $157.7 million.
R&D spending increased to $27.5 million from $18.4 million year over year.
The company said profits fell to $26.7 million from $34.5 million in the year-ago period.
Millipore said it had around $56.6 million in cash and cash equivalents as of March 31.

Caliper's Q1 Revenue Jumps 27 Percent as Losses Double; Firm Licenses Monogram Microfluidics IP
Caliper Life Sciences this week said first-quarter revenues increased 27 percent as R&D spending grew 29 percent to contribute to a 120-percent surge in net losses.
Total receipts for the three months ended March 31 increased to $28.4 million from $22.3 million year over year.
Product sales contributed $15.3 million, a 4-percent increase year over year; services brought in $8.9 million, a 77-percent increase; and licensing and contracts generated $4.3 million, or 66 percent better than last year.    
R&D spending increased to $5.8 million from $4.5 million year over year.
Caliper’s net losses increased to $9.6 million from $4.4 million.
 Caliper said it had around $9.9 million in cash and equivalents and $11.7 million in marketable securities as of March 31.
Caliper projects its 2007 revenue will be between $137 million and $143 million, or between 27 percent and 33 percent better than 2006.
Separately this week, the company said it has licensed microfluidics IP from Monogram. Financial details of the deal were not disclosed

PerkinElmer Opens New HQ and TechCenter
PerkinElmer this week opened its new corporate headquarters and technology center in Waltham, Mass. The 115,000-square-foot campus includes a research and development facility for PerkinElmer's drug discovery, cellular science, and diagnostics businesses. The event also marked PerkinElmer's 60th anniversary as a Massachusetts-based technology company.
Approximately 100 employees, customers, partners, and guests attended the event, which included a ribbon-cutting ceremony, facility tours, and reception.

Cellexus Settles Into New Digs
Cellexus Biosystems this week announced that it has relocated its headquarters to new offices and research laboratories in Huntingdon, Cambridgeshire, UK.
The facilities have been designed to house the company’s central operations, sales and marketing, and purpose-built research laboratories for the culture of bacterial, insect, and mammalian cells
The laboratories were designed by Julie Bick, Cellexus’ chief scientific officer. The labs were laid out so that scientists are able to culture a range of cells, especially mammalian cells.  
The company also said this week it has appointed London-based Capital MS&L as its public relations firm as it prepares to move to the AIM market of the London Stock Exchange.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.